Autologous bone marrow transplantation for Hodgkin's disease
- 1 September 1992
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 3 (suppl_4) , S95-S96
- https://doi.org/10.1093/annonc/3.suppl_4.s95
Abstract
Autologous bone marrow and/or peripheral blood stem cell transplantation is being performed increasingly frequently as a treatment for Hodgkin's disease. While patients with refractory disease can sometimes be cured, the results are better in patients who are still chemotherapy sensitive. The use of high dose therapy as part of the primary treatment for high risk patients is now being studied.Keywords
This publication has 8 references indexed in Scilit:
- Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.Journal of Clinical Oncology, 1991
- High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease [published erratum appears in Blood 1991 Dec 15;78(12):3330]Blood, 1991
- Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantationBlood, 1991
- Allogeneic marrow transplantation for refractory Hodgkin's disease.Journal of Clinical Oncology, 1989
- Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantationBlood, 1989
- High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's diseaseBritish Journal of Cancer, 1989
- Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantationBlood, 1989
- High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.Journal of Clinical Oncology, 1988